Nitrofurantoin Dosing Recommendations
For acute uncomplicated cystitis in women, prescribe nitrofurantoin monohydrate/macrocrystals 100 mg twice daily for 5 days. This represents the optimal balance between efficacy and minimizing antibiotic exposure based on high-quality guideline evidence 1, 2, 3.
Standard Dosing by Indication
Acute Uncomplicated Cystitis
- Women: 100 mg twice daily for 5-7 days 1
- Men: 100 mg twice daily for 7 days 4
- Alternative regimen: 100 mg four times daily for 3 days (macrocrystals formulation) 1
Recurrent UTI Prophylaxis
- 50 mg once daily is the preferred prophylactic dose 5
Vancomycin-Resistant Enterococci (VRE)
- Uncomplicated UTI: 100 mg four times daily for 3-7 days 6
Pregnancy-Specific Dosing
Pregnant women with asymptomatic bacteriuria require 100 mg twice daily for 7 days 7, 8. This is critical:
- Single-dose or 1-day regimens are significantly inferior in pregnancy 8
- 1-day regimen achieved only 75.7% cure versus 86.2% with 7-day regimen 8
- Shorter courses associated with lower birth weight and earlier gestational age at delivery 8
- Treatment prevents pyelonephritis and preterm labor 7
- Avoid in late pregnancy (near term) due to risk of hemolytic anemia in neonates 7
Pregnancy pharmacokinetics: Blood levels and renal excretion remain unchanged during pregnancy except during active labor, when renal elimination decreases and blood concentrations increase 9.
Renal Impairment Adjustments
Contraindicated when creatinine clearance <30 mL/min 10, 11:
- Inadequate urinary concentrations achieved below this threshold
- Increased risk of peripheral neuropathy with renal impairment 10
- The 2015 Beers Criteria updated the cutoff from <60 to <30 mL/min based on safety data 11
- Between 30-60 mL/min: Use with caution, monitor closely for adverse effects
Pediatric Dosing
Children >2 months: 5-7 mg/kg/day divided into 4 doses for treatment 6
- Maximum dose: 100 mg/dose
- Duration: 7 days or at least 3 days after sterile urine 6
- Not approved for children <12 years by some regulatory agencies 6
- Contraindicated in infants <1 month due to hemolytic anemia risk
Critical Safety Considerations
Absolute Contraindications
- CrCl <30 mL/min 10
- Infants <1 month of age
- Term pregnancy (38-42 weeks) and during labor
- G6PD deficiency 10
High-Risk Populations Requiring Monitoring
Monitor closely for peripheral neuropathy in patients with 10:
- Renal impairment (even CrCl 30-60 mL/min)
- Anemia
- Diabetes mellitus
- Electrolyte imbalance
- Vitamin B deficiency
- Debilitating diseases
Pulmonary Toxicity Warning
Chronic use (>6 months) carries significant pulmonary risk 10:
- Chronic pulmonary reactions manifest as malaise, dyspnea on exertion, cough
- Diffuse interstitial pneumonitis or fibrosis may be irreversible
- Risk increases with duration after first clinical signs appear
- Acute reactions occur within first week: fever, chills, chest pain, pulmonary infiltrates 10
Common Pitfalls to Avoid
Do not use nitrofurantoin for pyelonephritis - inadequate tissue penetration due to low serum concentrations 2, 3
Do not prescribe 3-day courses despite some UK guidance 12 - insufficient evidence supports this duration; 5-day minimum recommended by major guidelines 1, 2, 3, 4
Do not use 100 mg for prophylaxis - 50 mg daily provides equivalent efficacy with better tolerability 5
Do not use single-dose therapy except in non-pregnant women - fosfomycin is the appropriate single-dose agent, not nitrofurantoin 2, 3
Do not continue beyond 6 months without pulmonary assessment - chronic pulmonary fibrosis risk increases substantially 10
Formulation Considerations
Nitrofurantoin monohydrate/macrocrystals formulation is preferred over macrocrystals alone due to:
- Better gastrointestinal tolerability
- More consistent absorption
- Lower adverse event rates (5.6% vs 23-34% in comparative trials) 1
Take with food to minimize gastrointestinal side effects - nausea and anorexia are dose-related and reduced with food intake 10.